Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2021 | The AD pipeline and role of amyloid-beta

Jeffrey L. Cummings, MD, ScD, The University of Nevada, Reno, NV, provides an overview of his presentation at the AD/PD 2021 conference analyzing the Alzheimer’s disease (AD) therapeutic pipeline, which indicated that there is a significant focus on disease-modifying therapies and a growing diversification in the pipeline with rising trends in the study of tau protein, inflammation and synaptic protection. He also describes some highlights from the AD/PD symposium on the role of amyloid-beta in the pathophysiology of AD, which covered the genetics, biomarkers and clearance of amyloid-beta. This interview took place during the AD/PD™ 2021 conference.


Dr. Cummings has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies.